Access
Compounding pharmacies for semaglutide: what to verify now
Older pharmacy rankings relied on shortage-era assumptions. Current semaglutide compounding decisions need a patient-specific medical rationale and compliance with the applicable conditions.
Why shortage-era advice is outdated
FDA determined the tirzepatide shortage resolved in December 2024 and the semaglutide injection shortage resolved in February 2025. The agency's current clarification describes restrictions on regular or inordinate compounding of essentially copies under section 503A and separate conditions for 503B outsourcing facilities.
A website continuing to offer a product does not prove that the prescription and production meet those conditions. Nor does shortage resolution mean that every possible patient-specific compounded prescription is categorically prohibited. A clinician and pharmacist must assess the actual circumstances.
Sources: FDA clarification of compounding policies as GLP-1 supply stabilizes
Verify the actual dispensing entity
A telehealth platform may arrange care without manufacturing or dispensing medicine. Ask for the pharmacy's legal name, state license, physical location, and the product label. Review the license with the relevant state board, rather than relying on a platform logo or claim about a registered facility.
Registration or an outsourcing-facility listing is not FDA approval of the medicine. A laboratory certificate can describe a test, but it does not establish sterility, clinical outcomes, legal eligibility, or the identity of every vial you might receive.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Assess the formulation and instructions
FDA warns that semaglutide sodium and semaglutide acetate are different active ingredients from those in approved semaglutide products and should not be used in compounding. Ask the pharmacist to identify the exact ingredient and any additives.
Obtain dose, concentration, volume, syringe, storage, and beyond-use instructions for your own prescription. A compounded oral preparation does not inherit the approved tablet's absorption evidence or dosing schedule.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Questions for a clinician-led decision
Discuss whether an FDA-approved product can meet the medical need, what specific difference is necessary if it cannot, and what alternatives exist. Cost and coverage should be discussed honestly without converting affordability concerns into an unproven safety claim.
Ask how adverse events are handled and who provides follow-up. Evidence from branded-drug trials does not establish the compounded formulation's results. If the pharmacy or clinical rationale remains unclear, request documentation before treatment.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Separate pharmacy verification from formula evidence
A state license helps establish the pharmacy's authorization and identity. It does not make every preparation FDA-approved or prove that a particular formula has branded-drug efficacy. Ask for the legal pharmacy name, physical address, applicable license, and a pharmacist who can explain the actual prescription. Check those details through the relevant board rather than relying on a platform logo or testimonial.
Then ask about ingredients, route, concentration, dispensing instructions, storage, and beyond-use information. Injectable and oral preparations require different evidence questions. An oral compound does not acquire the studied absorption of Wegovy tablets merely because semaglutide appears on the label. Semaglutide sodium and acetate also should not be treated as the same active ingredient as the approved products. Verification needs both an identified pharmacy and an understood formula.
Sources: FDA BeSafeRx: checking an online pharmacy · FDA concerns with unapproved GLP-1 drugs used for weight loss
What a patient-specific rationale should explain
Current FDA guidance says a compounded drug should be used when a patient's medical needs cannot be met by an approved drug. Ask the clinician what specific need is being addressed and the pharmacy which applicable compounding pathway it uses. A general statement that every patient benefits from personalization leaves the actual rationale unclear.
The shortage-era ability to make copies cannot be assumed to continue indefinitely after shortage resolution. Section 503A and 503B have different conditions, and a small dose change or vitamin addition is not automatic proof of an exception. This page cannot adjudicate a particular prescription's legal compliance. It can help identify which explanation and documentation are missing so a reader does not mistake marketing language, affordability, or facility registration for approval evidence.
Sources: FDA clarification of compounding policies as GLP-1 supply stabilizes · FDA concerns with unapproved GLP-1 drugs used for weight loss
Recheck measurement at every changed refill
If the pharmacy, concentration, vial size, or formula changes, request updated written instructions linking prescribed milligrams to volume and the supplied syringe. An old direction in "units" may no longer match the vial. Ask the pharmacist to demonstrate the measurement and reconcile any conflict between the label and the portal message before injecting.
Also ask how to report a suspected quality problem or adverse event and how quickly a clinical concern can reach the prescriber. A certificate describing a sample is not an audit of every vial, the clinical decision, or all dispensing practices. We do not identify a pharmacy as best without that evidence. A useful evaluation focuses on the actual prescription, current rules, clear measurement, and accessible follow-up rather than an unsupported numerical score.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA BeSafeRx: checking an online pharmacy
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.